DiaMedica Announces First Patients Dosed in Diabetic Kidney Disease Cohort in Phase II REDUX CKD Clinical Study
Stock Information for DiaMedica Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.
More Recent News About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results